Paris La Défense, FRANCE – March 17, 2026: SGD Pharma, world leader in the market for pharmaceutical glass primary packaging solutions, announces a Franco-American strategic OEM collaboration with Prince Sterilization Services, LLC to validate ready-to-use (RTU) Type I glass primary packaging solutions for the North‐American market. The first concrete result of this collaboration is the My Sterinity Nasal platform, a new flexible range of vials cleaned within SGD Pharma’s RTU My Sterinity platform, using the company’s U‐Save type I vials, designed to meet the growing segment of nasal administration of high value-added drugs. The launch will be presented at DCAT Week 2026, which will take place from March 23 to 26 in New York.

My Sterinity Nasal is the first platform resulting from the collaboration between SGD Pharma and Prince, combining SGD Pharma’s expertise in manufacturing type I glass and Prince’s know-how in sterilization services. Initially available in 3.5 mL, 7.5 mL and 10 mL clear or amber glass formats, My Sterinity Nasal offers key benefits for high-value nasal therapies:

  • Controlled levels of particles and endotoxins for enhanced purity
  • Biologically inert Type I sterile glass, without the need for preservatives (reducing the risk of inflammation)
  • Validated sterility guarantee
  • Compatibility with standard preservative-free nasal pump systems
  • Packaging in double‐packaged trays for an RTU presentation

The new My Sterinity Nasal vials support the administration of sensitive nasal medications with a high quality primary packaging that protects the medication and ensures its stability, safety and efficacy. The production of the range will take place at SGD Pharma’s flagship site in Saint‐Quentin‐La‐Motte (SQLM), in northern France, while Prince will provide washing, depyrogenation and sterilization services in North America, ensuring a validated regional supply chain for US biopharmaceutical customers.

The global nasal market is estimated at 9 billion euros, with more than 2 billion units, historically dominated by plastic (about 88%). However, glass offers superior chemical inertia, barrier protection and long-term biocompatibility – essential criteria for preserving product integrity, minimizing adsorption and ensuring sterility in chronic use therapies. Long focused on acute treatments, the nasal market is now turning towards more advanced and long-term treatments, such as Alzheimer’s, Parkinson’s, multiple sclerosis, or depression, requiring primary conditioning combining sterility, consistency, and precise dosage, making type I glass the material of choice to preserve long-term therapeutic stability.

Carole Grassi, Chief Commercial, Marketing & Innovation Officer at SGD Pharma, states:
"Our collaboration with Prince marks an important step in SGD Pharma’s innovation growth strategy in North America. The My Sterinity Nasal platform represents a major breakthrough in nasal administration of high-value medications, and our collaboration with Prince opens up an immediately qualified US‐based capacity to support biopharma clients in the expansion of complex nasal programs. This is more than just a product launch: it’s a validated supply chain, ready to support qualification, clinical trials and commercial launch with unparalleled speed and reliability.”

Daniel Prince, Ph.D., CEO of Prince, adds:
'SGD Pharma’s expertise in type I glass, combined with our flexible and quality-oriented RTU and sterilization platform, creates the absolute reference for sterile nasal packaging. The recent U.S. qualification of Prince now enables us to provide ready-to-use, end-sterilized My Sterinity Nasal vials within timelines aligned with national and international development cycles and exceeding quality requirements.”

At DCAT 2026, SGD Pharma will also highlight its growing portfolio of innovative glass solutions designed to enhance medication integrity, patient safety and operational efficiency, including:

  • SEALIAN, a high-performance internal treatment that improves chemical durability and provides superior protection for sensitive drugs. SEALIAN received the 2025 Pharmaceutical Gold Award at the New Jersey Packaging Executive Club (NJPEC) Packaging of the Year Awards.
  • Filling/finishing lines require robust vials with excellent inspection capabilities. IDENCY premium bottles have a higher chemical and mechanical resistance than standard tubular bottles and maintain the same outer diameter to facilitate their integration into existing lines.

Heather Moore, Vice-President of Americas Sales, adds:
"SGD Pharma is a reliable and efficient partner, able to help customers scale, qualify or develop new products quickly with confidence. As the industry adapts to changing supply chain dynamics, The addition of My Sterinity Nasal to SGD Pharma’s production lines increases the available capacity in the U.S. market for Type I molded glass vials. SGD Pharma’s Type I molded glass portfolio offers:

  • Exceptional stability: superior chemical durability and high hydrolytic resistance
  • Excellent heat resistance: low thermal expansion provides additional protection during lyophilization or autoclaving
  • Mechanical resistance: better structural integrity, reducing the risk of breakage during filling and transport
  • Accelerated lead times: thanks to available capacity, SGD Pharma offers reduced lead times and prioritized planning

In our annual customer satisfaction survey, respondents rated SGD Pharma as a top performer for its molded glass products (97% satisfaction), with 70% citing their superior quality. The vast majority of respondents are loyal to SGD Pharma: 98% say they will continue to work with us in the future, demonstrating their confidence in our company for their future vial needs.”

During DCAT Week 2026, the global team of SGD Pharma will meet partners and customers to explore new collaborations and present its latest innovations in pharmaceutical glass packaging.
To schedule a meeting, please contact: Marie-Christine.Revereau@sgdgroup.com

.